~ Buy the RYDAPT (midostaurin) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR RYDAPT

All Clinical Trials for Rydapt

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01830361 ↗	Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML	Completed	Novartis Pharmaceuticals	Phase 2	2013-03-13	To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
NCT01830361 ↗	Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML	Completed	Technische Universität Dresden	Phase 2	2013-03-13	To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
NCT02115295 ↗	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 2	2014-05-19	This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT02115295 ↗	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Recruiting	M.D. Anderson Cancer Center	Phase 2	2014-05-19	This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT02723435 ↗	Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant	Withdrawn	National Cancer Institute (NCI)	Phase 2	1969-12-31	This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.
NCT02723435 ↗	Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant	Withdrawn	Stanford University	Phase 2	1969-12-31	This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.
NCT03092674 ↗	Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Active, not recruiting	National Cancer Institute (NCI)	Phase 2/Phase 3	2017-12-22	This randomized phase II/III trial studies how well azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone work in treating older patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as azacitidine, decitabine, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Midostaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone may kill more cancer cells.

Clinical Trial Conditions for Rydapt

Condition Name

Condition Name for Rydapt
Intervention	Trials
Acute Myeloid Leukemia	10
Untreated Adult Acute Myeloid Leukemia	2
Myelodysplastic Syndrome	2
Myelodysplastic Syndrome With Excess Blasts-2	2

Condition MeSH

Condition MeSH for Rydapt
Intervention	Trials
Leukemia, Myeloid, Acute	11
Leukemia, Myeloid	11
Leukemia	10
Syndrome	3

Clinical Trial Locations for Rydapt

Trials by Country

Trials by Country for Rydapt
Location	Trials
United States	82
Germany	5
Netherlands	2
Switzerland	1

Trials by US State

Trials by US State for Rydapt
Location	Trials
Florida	4
California	4
Georgia	3
Washington	3
Tennessee	3

Clinical Trial Progress for Rydapt

Clinical Trial Phase

Clinical Trial Phase for Rydapt
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	6

Clinical Trial Status

Clinical Trial Status for Rydapt
Clinical Trial Phase	Trials
Recruiting	5
Withdrawn	2
Active, not recruiting	2

Clinical Trial Sponsors for Rydapt

Sponsor Name

Sponsor Name for Rydapt
Sponsor	Trials
Novartis Pharmaceuticals	3
National Cancer Institute (NCI)	3
Pfizer	2

Sponsor Type

Sponsor Type for Rydapt
Sponsor	Trials
Other	14
Industry	9
NIH	3